Published: June 2025 | Last updated: May 2026
The bacterium that causes gonorrhoea has been outrunning antibiotics for nearly a century. Each new drug class works for a few decades, then loses ground. Today's first-line treatment is a single intramuscular injection of ceftriaxone, and it still cures most infections. But resistance is building in pockets across Europe, Asia, and now North America, and the World Health Organization classifies Neisseria gonorrhoeae as a high-priority pathogen for antimicrobial resistance surveillance. "Super-gonorrhoea" is the informal name for strains that resist one or more frontline drugs, sometimes requiring extended intravenous therapy to clear. This article walks through what the 2026 resistance picture actually looks like, which tests can detect the infection and which can flag resistance, and where at-home rapid kits realistically fit in.
Why gonorrhoea adapts faster than most STIs
Three biological features make Neisseria gonorrhoeae unusually good at acquiring resistance. First, it is naturally competent, meaning it readily takes up DNA from its environment, including resistance genes shed by other bacteria living in the same anatomical site. Second, it divides quickly under optimal conditions, so a small population of bacteria with a useful mutation can dominate a colony within hours. Third, it persists silently in the throat and rectum, where it sits in a low-grade chemical environment that includes leftover antibiotics from past prescriptions, food, and toothpaste. Sub-therapeutic exposure to drugs is exactly the condition under which resistance evolves.
Layer on top of that biology a few human factors. Pharyngeal gonorrhoea is usually asymptomatic, so it goes untreated longer. People with new partners may not get screened at the throat or rectum even though that is where their exposure happened. Antibiotic-prescribing patterns vary widely between countries, with over-the-counter sales in some regions making sub-therapeutic exposure easy without the user intending it.
Natural genetic competence (it picks up DNA from neighbouring bacteria), fast doubling time (useful mutations can dominate within hours), and silent pharyngeal persistence (long untreated exposure to sub-therapeutic antibiotics in saliva and food residues). Together these turn the throat in particular into a quiet resistance workshop.
A short history of gonorrhoea outsmarting antibiotics
Sulfa drugs arrived in the 1930s and worked for roughly a decade before resistance emerged. Penicillin came next, and was the standard of care until widespread resistance ended its usefulness for gonorrhoea by the late 1980s. Tetracyclines fell in the 1990s. Fluoroquinolones (ciprofloxacin, ofloxacin) lost reliability through the 2000s and were dropped from CDC and WHO guidelines for gonorrhoea by 2007. Each drug had a useful life of roughly 20 to 40 years.
The current standard is a 500 mg (or 1 g, depending on guideline) intramuscular dose of ceftriaxone, a third-generation cephalosporin. For more than a decade this has cured the overwhelming majority of cases. Laboratories in the United Kingdom, Japan, Australia, and the United States have now cultured strains with reduced ceftriaxone susceptibility, including a small cluster of confirmed treatment failures. Researchers have catalogued specific mutations in the penA gene that lower ceftriaxone's activity.
| Drug class | First-line era | Status today |
|---|---|---|
| Sulfonamides | 1930s to early 1940s | Resistance ended use |
| Penicillin | 1940s to late 1980s | Resistance ended use |
| Tetracyclines | 1970s to 1990s | Resistance ended use |
| Fluoroquinolones | 1980s to 2007 | Dropped from CDC and WHO guidelines |
| Ceftriaxone (cephalosporin) | 2010s to present | Current first line, with reduced-susceptibility strains emerging |
Where resistance gets its start: the throat as a quiet reservoir
Pharyngeal gonorrhoea is the lesson everyone learns slowly. Most infections at this site produce no symptoms, or at most a mild sore throat people attribute to a cold. Without symptoms there is no trigger to test, so infections can persist for months. During that time the bacteria sit in the same tissue as Neisseria meningitidis and other related bacteria, and they exchange genetic material. Several of the resistance mutations now circulating in gonorrhoea were almost certainly acquired this way.
This is also why focusing screening only on genital sites misses a meaningful share of infections. If you had unprotected oral sex with a new partner, a urine test alone is not enough to rule out gonorrhoea. A throat swab is the diagnostic that matches that exposure.
CDC recommends extragenital (throat and rectal) testing for anyone whose recent exposures included oral or anal sex, regardless of orientation. A genital swab or urine sample alone will miss pharyngeal and rectal infections, which are usually asymptomatic.
The gap between detecting infection and predicting treatment success
Two very different testing technologies are used for gonorrhoea, and the difference matters.
Nucleic acid amplification tests (NAATs) look for the genetic material of N. gonorrhoeae in a sample. They are highly sensitive, can use a swab or urine sample, and return a result in hours to a day in a laboratory setting. CDC considers NAATs the test of choice for diagnosis. What they do not do is tell you which antibiotics will work. NAATs answer the yes-or-no question of whether the bacteria are present, but they do not grow the bacteria, so they cannot perform susceptibility testing.
Culture, by contrast, grows the bacteria on selective media. Once cultured, the isolate can be tested against a panel of antibiotics to identify which ones still inhibit growth. This is the gold standard for resistance characterisation, but it takes 24 to 72 hours, requires a fresh sample collected with a charcoal swab and proper transport conditions, and depends on a lab equipped to do it. Many clinics no longer routinely culture gonorrhoea because NAATs are faster for diagnosis. The unintended consequence is reduced surveillance capacity for resistance.
Rapid at-home lateral-flow tests sit in a third category. They detect specific gonorrhoea antigens at the swabbed site within minutes, are useful for an initial screen, and are not equivalent to a laboratory NAAT in sensitivity. They do not characterise resistance either.
Can an at-home test tell me if I have a drug-resistant strain?
No. At-home rapid lateral-flow tests, and standard laboratory NAATs, both detect whether N. gonorrhoeae is present. Neither identifies which antibiotics will work. That requires a culture and antibiotic susceptibility test, ordered by a clinician on a fresh sample collected with the correct swab. If a first-line treatment fails to clear your symptoms, that is the time to ask for one.
How rapid antimicrobial susceptibility testing is starting to change the picture
Research groups in the US, UK, and Singapore have developed faster susceptibility-testing methods that compress the 48 to 72 hour culture-based timeline into a few hours. Some use direct genotyping, scanning the sample for known resistance-conferring mutations. Others use phenotypic readouts on much smaller bacterial populations than traditional culture requires. None are yet broadly deployed as point-of-care devices, and most are still in research or early clinical-trial settings.
The promise is real: same-visit susceptibility data would let clinicians prescribe the right antibiotic the first time, preserving the activity of newer drugs for the cases that actually need them. The challenge is regulatory clearance, cost, and the practical reality that adopting any new diagnostic in a busy STI clinic takes years. For the foreseeable future, the diagnostic stack will look like a rapid or laboratory NAAT confirming the infection, with culture reserved for treatment failures and surveillance samples.
The leading research approaches fall into two camps. Direct genotyping scans a sample for known resistance-conferring mutations using a PCR-style readout, skipping the need to grow bacteria at all. Phenotypic micro-AST measures bacterial growth or metabolism on much smaller populations than traditional culture, compressing a 48 to 72 hour result into a few hours. Both are in research or early clinical-trial use as of 2026, not yet point-of-care devices in most clinics.
How at-home rapid swab kits fit into the resistance picture
This article is published by STD Rapid Test Kits, which sells the at-home rapid tests described here. We recommend products based on fit-for-purpose for the reader's concern, not commercial benefit.
At-home kits are a screening tool, not a substitute for clinic care. They lower the barrier for people who would otherwise delay testing, since an anonymous, discreet, fifteen-minute test is a meaningful upgrade over scheduling a clinic appointment for a lot of users, and a faster positive means a faster trip to treatment. They also make routine retesting after potential exposures more practical, and they prompt exactly the kind of clinic visit where a clinician will order a culture, which is what resistance surveillance needs.
Our at-home gonorrhoea rapid test is a lateral-flow immunoassay. Laboratory NAATs have higher analytical sensitivity, especially for asymptomatic infections, and remain the standard of care for diagnosis. A negative at-home result after a known exposure does not rule out infection with the same confidence a NAAT does, so anyone with persistent symptoms or a known partner diagnosis should still confirm with clinic testing. Any at-home positive should be followed by clinician-led treatment, ideally with a culture taken before the antibiotic is given so resistance can be tracked.
One additional point about sample type. Our genital swab is validated for self-collection at the genital site. If your potential exposure was oral or anal, a clinic visit for a throat or rectal swab is the diagnostic that matches what happened. We do not sell a pharyngeal or rectal swab kit, and substituting a genital test for either of those is the wrong tool for the question.
Genome surveillance: why it matters even if you never see it
Behind the scenes, reference laboratories sequence positive gonorrhoea isolates and upload the genomes to shared surveillance networks like the WHO Gonococcal Antimicrobial Surveillance Programme (GASP). Each genome is checked against a database of known resistance markers. This lets epidemiologists track when a high-resistance strain crosses a border, identify clusters early, and update local treatment guidelines before a regional outbreak becomes a national one.
The system has obvious limits. Sequencing capacity is concentrated in higher-income countries, so many infections in regions with the highest resistance pressure are never genotyped. The system also depends on clinics actually culturing positive samples, which is happening less often as NAATs replace culture for routine diagnosis. For an individual patient the practical step is small but useful: if a first-line treatment fails, ask your clinician to send the isolate for resistance characterisation.
The Gonococcal Antimicrobial Surveillance Programme collects susceptibility data from sentinel laboratories in dozens of countries. It is the system that flags new resistance patterns early. Lower-income regions with the heaviest resistance burden are the least well-represented because of sequencing-capacity gaps.
Gepotidacin and the rest of the antibiotic pipeline
Gepotidacin is the most clinically advanced of the recent candidates. The 2024 EAGLE-1 phase 3 trial in adults with uncomplicated urogenital gonorrhoea showed cure rates broadly comparable to a ceftriaxone-plus-azithromycin comparator arm (reflecting the prior dual-therapy guideline, since superseded in the US by ceftriaxone monotherapy), with the advantage of being a single-dose oral regimen. Regulatory review for the gonorrhoea indication is ongoing in multiple jurisdictions as of early 2026.
Zoliflodacin is another candidate in late-stage development, also studied as a single oral dose. Both drugs use mechanisms that are mostly unaffected by the resistance mutations driving ceftriaxone concerns. The same lesson from every previous drug applies though: a new antibiotic introduced into widespread use without diagnostic gatekeeping eventually selects for resistance against itself. Regulatory clearance and clinic adoption of rapid susceptibility testing will determine how quickly the deployment of these candidates can be targeted.
Vaccines: real progress, but not a near-term substitute for testing
Trial results for a meningococcal B vaccine that incidentally cross-protected against gonorrhoea, plus more recent work on gonorrhoea-specific candidates, have moved a vaccine from a long-shot idea to an active development pipeline. Some candidates are now in mid-stage clinical trials. Even an imperfect vaccine that lowers transmission by a moderate amount would change the resistance picture, because fewer infections means fewer opportunities for resistance traits to spread.
For now though, no licensed gonorrhoea vaccine exists. Testing remains the primary defence at the individual level, condoms remain effective for genital and rectal exposures (less so for oral), and treating known infections quickly is what most directly slows resistance spread.
No licensed gonorrhoea vaccine exists as of 2026. The combination of regular testing at all relevant anatomical sites, condom use for genital and rectal exposures, and prompt treatment of any confirmed infection remains the practical defence.
How often you should actually test
There is no single right interval. The useful framing is to match testing to your actual risk pattern.
An at-home rapid kit is useful between scheduled clinic screens or when an unexpected concern arises. A clinic-based NAAT remains the standard for confirming a positive, ruling out other infections in the same panel, and getting treatment.
If your symptoms return after treatment
Most return-of-symptoms after a ceftriaxone dose is reinfection from an untreated partner, not resistance. The first questions to answer are: was your partner treated, did either of you have sex before the seven-day post-treatment window CDC recommends abstaining for, and could there have been a new exposure since.
If reinfection is genuinely unlikely, the next step is a return visit and, ideally, a culture. Ask specifically for a culture rather than another NAAT, because only culture allows the lab to perform susceptibility testing. If your clinic does not routinely culture, you can ask for a referral to one that does, or to a sexual-health specialist. This matters not only for your treatment, but because that isolate may be the one that flags a new resistance pattern to the surveillance network.
Confirmed resistant infections are managed with individualised antibiotic regimens, sometimes intravenous, based on what the susceptibility test shows. Combinations of ertapenem and other agents have been used for documented cases, and gepotidacin will likely become a guideline-recommended option as regulatory review concludes.
Symptoms that return within a few weeks of a ceftriaxone injection are not automatically a sign of resistance. Reinfection from an untreated partner is far more common. Persistent symptoms do warrant a return visit, ideally with a culture and antibiotic susceptibility test rather than another empirical dose of the same drug.
Antimicrobial resistance in gonorrhoea has increased rapidly in recent years and has reduced the options for treatment.
Frequently asked questions
- Does super-gonorrhoea cause different symptoms from regular gonorrhoea?
- No. The clinical presentation is the same: urethral or vaginal discharge, burning urination, throat or rectal symptoms in some cases, or no symptoms at all. The difference shows up only when a standard course of ceftriaxone fails to clear the infection.
- Can I get gonorrhoea from oral sex?
- Yes. Pharyngeal gonorrhoea is transmitted through oral contact with an infected genital or anal site, and from oral sex received by an infected throat. Most pharyngeal infections produce no symptoms, which is why throat swabbing is recommended for anyone whose exposures included oral sex with new partners.
- Will condoms fully protect against gonorrhoea?
- Condoms substantially reduce transmission for vaginal and anal sex and offer partial protection for oral sex, but they do not cover all skin surfaces involved in transmission. Combined with regular testing, they are the most practical layer of protection. Dental dams cover the relevant area during oral-vaginal or oral-anal contact.
- Is there an at-home test that detects whether the strain is resistant?
- No. Confirming resistance requires a culture grown in a lab from a fresh sample, followed by antibiotic susceptibility testing, which is the same step a clinician orders after a first-line treatment failure. Standard home rapid tests and lab NAATs only answer whether the bacteria are present; they cannot identify which drugs will work.
- How soon after a possible exposure should I test?
- Most laboratory NAATs can detect gonorrhoea reliably from around 1 to 2 weeks post-exposure. Testing earlier than that risks a false negative. If a test at one week is negative but symptoms develop or persist, retest at 2 to 3 weeks. For at-home rapid tests, the same window-period logic applies.
- Does ceftriaxone still work in most cases?
- Yes. In most regions, a single intramuscular dose of ceftriaxone still cures the overwhelming majority of uncomplicated gonorrhoea infections. Resistance pockets are documented but remain a minority of cases. Surveillance is what flags new pockets early, which is why culture-based follow-up of treatment failures matters.
- What happens if my treatment fails?
- Return to a clinician for a repeat assessment. The right next step is usually a culture, ideally taken before any second course of antibiotics, so the isolate can be susceptibility-tested. Treatment for confirmed resistant infections is individualised based on what the lab report shows and may involve different drug classes, sometimes given intravenously.
- Can I test too often?
- No. Frequent testing is medically harmless and is recommended for anyone with a higher-risk pattern of exposure. The only downside is cost. For most users, testing more often than the calendar suggests is a question of personal budget rather than a clinical concern.
- World Health Organization. Multi-drug-resistant gonorrhoea fact sheet, covering global resistance trends, treatment-failure risk, and surveillance recommendations.
- U.S. Centers for Disease Control and Prevention. Drug-resistant Neisseria gonorrhoeae clinical guidance for healthcare providers, including current first-line treatment and culture-based follow-up of treatment failures.
- U.S. Centers for Disease Control and Prevention. Gonorrhea topic hub, covering symptoms, testing recommendations, and extragenital screening guidance for oral and anal exposures.
- NHS. Gonorrhoea condition page, covering UK clinical guidance on testing, treatment, and follow-up after treatment failure.
- European Centre for Disease Prevention and Control. Gonorrhoea topic page, covering European surveillance trends and antimicrobial resistance reporting.
- World Health Organization. Sexually transmitted infections fact sheet, covering global incidence, transmission routes, and screening recommendations.
